Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Chengzi I. Kaku"'
Autor:
Chengzi I. Kaku, Tyler N. Starr, Panpan Zhou, Haley L. Dugan, Paul Khalifé, Ge Song, Elizabeth R. Champney, Daniel W. Mielcarz, James C. Geoghegan, Dennis R. Burton, Raiees Andrabi, Jesse D. Bloom, Laura M. Walker
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-13 (2023)
Abstract Understanding the longitudinal dynamics of antibody immunity following heterologous SAR-CoV-2 breakthrough infection will inform the development of next-generation vaccines. Here, we track SARS-CoV-2 receptor binding domain (RBD)-specific an
Externí odkaz:
https://doaj.org/article/37c3f7bee51f4b23946f80718a893c6d
Autor:
Hejun Liu, Chengzi I. Kaku, Ge Song, Meng Yuan, Raiees Andrabi, Dennis R. Burton, Laura M. Walker, Ian A. Wilson
Publikováno v:
Communications Biology, Vol 5, Iss 1, Pp 1-13 (2022)
Structural and computational analyses reveal a recurring YYDRxG motif in a class of human antibodies that target a conserved epitope on sarbecoviruses including the Omicron variant.
Externí odkaz:
https://doaj.org/article/b9b16a64285c49bd8d3f55aace51b25b
Autor:
Benjamin S. Goldberg, Chengzi I. Kaku, Jérémy Dufloo, Timothée Bruel, Olivier Schwartz, David A. Spencer, Ann J. Hessell, Margaret E. Ackerman
Publikováno v:
mBio, Vol 12, Iss 5 (2021)
Given the suboptimal outcome of VRC01 antibody-mediated prevention of HIV-1 infection in its first field trial, means to improve diverse antiviral activities in vivo
Externí odkaz:
https://doaj.org/article/2dd32301729747d99f4ba9482f576cd2
Autor:
Pete Schmidt, Kristin Narayan, Yong Li, Chengzi I. Kaku, Michael E. Brown, Elizabeth Champney, James C. Geoghegan, Maximiliano Vásquez, Eric M. Krauland, Thomas Yockachonis, Shuangyi Bai, Bronwyn M. Gunn, Anthony Cammarata, Christopher M. Rubino, Paul Ambrose, Laura M. Walker
Publikováno v:
Science Translational Medicine. 15
Multiple studies of vaccinated and convalescent cohorts have demonstrated that serum neutralizing antibody (nAb) titers correlate with protection against coronavirus disease 2019 (COVID-19). However, the induction of multiple layers of immunity after
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9b87a929ceba729ff3942f02dbc8a1fb
https://doi.org/10.1126/scitranslmed.adg2783
https://doi.org/10.1126/scitranslmed.adg2783
Autor:
Elizabeth E. Zumbrun, Chengzi I. Kaku, Lukas Dillinger, Samantha E. Zak, Ana I. Kuehne, Russel R. Bakken, Jeffrey W. Koehler, Korey L. Delp, Christopher P. Stefan, Raina Kumar, Jeffrey R. Kugelman, Alicia M. Moreau, Xiankun Zeng, John M. Dye, Andrew S. Herbert, Kristin Narayan, Laura M. Walker
Publikováno v:
Antimicrobial Agents and Chemotherapy. 67
Adintrevimab is a human immunoglobulin G1 monoclonal antibody engineered to have broad neutralization against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and other SARS-like coronaviruses with pandemic potential. In both Syr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97fec6fc2a2ef5b4ce33805a6f7cd6aa
https://doi.org/10.1128/aac.01353-22
https://doi.org/10.1128/aac.01353-22
Autor:
Pete Schmidt, Kristin Narayan, Yong Li, Chengzi I. Kaku, Michael E. Brown, Elizabeth Champney, James C. Geoghegan, Maximiliano Vásquez, Eric M. Krauland, Thomas Yockachonis, Shuangyi Bai, Bronwyn M. Gunn, Anthony Cammarata, Christopher M. Rubino, Laura M. Walker
Publikováno v:
medRxiv
Multiple studies of vaccinated and convalescent cohorts have demonstrated that serum neutralizing antibody (nAb) titers correlate with protection against COVID-19. However, the induction of multiple layers of immunity following SARS-CoV-2 exposure ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14b11b2c4bdea6c95499b1a7f867d120
https://europepmc.org/articles/PMC9603828/
https://europepmc.org/articles/PMC9603828/
Autor:
Chengzi I. Kaku, Tyler N. Starr, Panpan Zhou, Haley L. Dugan, Paul Khalifé, Ge Song, Elizabeth R. Champney, Daniel W. Mielcarz, James C. Geoghegan, Dennis R. Burton, Raiees Andrabi, Jesse D. Bloom, Laura M. Walker
Publikováno v:
bioRxiv : the preprint server for biology.
Understanding the longitudinal dynamics of antibody immunity following heterologous SAR-CoV-2 breakthrough infection will inform the development of next-generation vaccines. Here, we track SARS-CoV-2 receptor binding domain (RBD)-specific antibody re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0be99ed8026d438de17810e054b41ea2
https://pubmed.ncbi.nlm.nih.gov/36172124
https://pubmed.ncbi.nlm.nih.gov/36172124
Autor:
Chengzi I. Kaku, Alan J. Bergeron, Clas Ahlm, Johan Normark, Mrunal Sakharkar, Mattias N. E. Forsell, Laura M. Walker
Publikováno v:
Science immunology. 7(73)
Understanding immune responses after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection will facilitate the development of next-generation vaccines. Here, we profiled spike (S)–specific B cell responses after Omicro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c35b53c9c6ef99c47af0afff7eb0852
https://pubmed.ncbi.nlm.nih.gov/35653497
https://pubmed.ncbi.nlm.nih.gov/35653497
Autor:
Chengzi I. Kaku, Alan J. Bergeron, Clas Ahlm, Johan Normark, Mrunal Sakharkar, Mattias N. E. Forsell, Laura M. Walker
Understanding immune responses following SARS-CoV-2 breakthrough infection will facilitate the development of next-generation vaccines. Here, we profiled spike (S)-specific B cell responses following Omicron/BA.1 infection in mRNA-vaccinated donors.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6004487da296b98a1c87f5495ce57821
https://doi.org/10.1101/2022.04.01.486726
https://doi.org/10.1101/2022.04.01.486726
Autor:
Meng Yuan, Xueyong Zhu, Wan-ting He, Panpan Zhou, Chengzi I. Kaku, Tazio Capozzola, Connie Y. Zhu, Xinye Yu, Hejun Liu, Wenli Yu, Yuanzi Hua, Henry Tien, Linghang Peng, Ge Song, Christopher A. Cottrell, William R. Schief, David Nemazee, Laura M. Walker, Raiees Andrabi, Dennis R. Burton, Ian A. Wilson
Many neutralizing antibodies (nAbs) elicited to ancestral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) through natural infection and vaccination have reduced effectiveness to SARS-CoV-2 variants. Here, we show that therapeutic antibod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44bb4cfaa379de02d1c1df7acae0804a
https://doi.org/10.1101/2022.03.13.484037
https://doi.org/10.1101/2022.03.13.484037